Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Study for the Detection of Nephrogenic Systemic Fibrosis in Patients With Renal Impairment Undergoing Gadoversetamide-enhanced Magnetic Resonance Imaging

Trial Profile

A Prospective Study for the Detection of Nephrogenic Systemic Fibrosis in Patients With Renal Impairment Undergoing Gadoversetamide-enhanced Magnetic Resonance Imaging

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gadoversetamide (Primary)
  • Indications Kidney disorders; Renal failure
  • Focus Diagnostic use; Registrational
  • Acronyms SHERLOC
  • Sponsors Mallinckrodt Medical
  • Most Recent Events

    • 20 Jul 2017 Planned End Date changed from 1 Feb 2013 to 17 May 2012.
    • 20 Jul 2017 Planned primary completion date changed from 1 Feb 2013 to 17 May 2012.
    • 20 Jul 2017 Status changed from suspended to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top